Other research analysts have also recently issued research reports about the company. Zacks Investment Research raised Oxford Immunotec Global from a hold rating to a buy rating and set a $19.00 price target on the stock in a research report on Wednesday, March 13th. ValuEngine cut Oxford Immunotec Global from a strong-buy rating to a buy rating in a report on Tuesday, March 12th. Finally, TheStreet raised Oxford Immunotec Global from a d rating to a c- rating in a report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $18.00.
Shares of NASDAQ OXFD opened at $14.07 on Thursday. Oxford Immunotec Global has a one year low of $11.66 and a one year high of $19.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.03 and a current ratio of 12.60. The firm has a market cap of $374.59 million, a PE ratio of 27.59 and a beta of 0.42.
In related news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total transaction of $48,150.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $48,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Wrighton-Smith sold 10,600 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $16.68, for a total value of $176,808.00. Following the sale, the chief executive officer now directly owns 445,138 shares in the company, valued at approximately $7,424,901.84. The disclosure for this sale can be found here. Corporate insiders own 6.61% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its stake in Oxford Immunotec Global by 59,988.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock worth $93,000 after acquiring an additional 5,399 shares during the last quarter. Squarepoint Ops LLC increased its stake in Oxford Immunotec Global by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock worth $247,000 after acquiring an additional 5,120 shares during the last quarter. Rhumbline Advisers increased its stake in Oxford Immunotec Global by 50.7% in the 4th quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock worth $419,000 after acquiring an additional 11,022 shares during the last quarter. Acadian Asset Management LLC increased its stake in Oxford Immunotec Global by 972.3% in the 1st quarter. Acadian Asset Management LLC now owns 33,969 shares of the company’s stock worth $586,000 after acquiring an additional 30,801 shares during the last quarter. Finally, Bessemer Group Inc. bought a new position in Oxford Immunotec Global in the 4th quarter worth about $778,000. Institutional investors and hedge funds own 91.57% of the company’s stock.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Recommended Story: What are Bollinger Bands?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.